Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
Filed with ASX · · 2 pages · English
® ® An independent safety committee, recently, unanimously concluded R327 is safe and well tolerated in male and female subjects at an infusion rate of 3000mg (I.V.), over 30 minutes. Since the previous cohort dosed, the Committee approved a faster infusion rate, double that of what was previously delivered over 30 minutes, now being delivered at 3,000mg over 15- Chief Executive Officer James Grah
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
- Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
- Placement and Entitlement Offer
- Opening R&D Address at World AMR Congress
- RECCE Trademark Registered - Vietnam
Later from Recce Pharmaceuticals
- Canadian Patent Granted for RECCE Anti-Infectives
- Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
- RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
- RCE Awarded Further $11.17m Advanced Overseas Finding
- Murdoch Children's R327 Efficacy UTI in-vivo
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals